Synergy Pharmaceuticals Presents Poster on Novel Mechanism of Action of SP-333, an Agonist of Guanylate Cyclase-C for Treatment of Ulcerative Colitis

[at noodls] – Scientific Poster Presentation at 2012 Advances in IBD Conference NEW YORK, Dec. 14, 2012 — Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and … more

View todays social media effects on SGYPU

View the latest stocks trending across Twitter. Click to view dashboard

See who Synergy is hiring next, click here to view